Table 2.
Relationship between DCAF13 expression and clinicopathological characteristics
| Group | Case(percent) | DCAF13 expression | p valuea | |||
|---|---|---|---|---|---|---|
| low | high | |||||
|
gender n = 90 |
total | 90 | 27 | 63 | ||
| female | 36 | (40.00%) | 14 | 22 | 0.162 | |
| male | 54 | (60.00%) | 13 | 41 | ||
|
age n = 90 |
total | 90 | 27 | 63 | ||
| ≤ 55 | 23 | (25.56%) | 4 | 19 | 0.187 | |
| >55 | 67 | (74.44%) | 23 | 44 | ||
|
grade n = 90 |
total | 90 | 27 | 63 | ||
| 1 | 7 | (7.78%) | 5 | 2 | 0.010 | |
| 2 | 55 | (61.11%) | 18 | 37 | ||
| 3 | 28 | (31.11%) | 4 | 24 | ||
|
stage n = 89 |
total | 89 | 27 | 62 | ||
| 1 | 31 | (34.83%) | 11 | 20 | 0.797 | |
| 2 | 20 | (22.47%) | 6 | 14 | ||
| 3 | 37 | (41.57%) | 10 | 27 | ||
| 4 | 1 | (1.12%) | 0 | 1 | ||
|
T n = 86 |
total | 86 | 26 | 60 | ||
| 1 | 18 | (20.93%) | 5 | 13 | 0.894 | |
| 2 | 48 | (55.81%) | 16 | 32 | ||
| 3 | 15 | (17.44%) | 4 | 11 | ||
| 4 | 5 | (5.81%) | 1 | 4 | ||
|
N n = 77 |
total | 77 | 22 | 55 | ||
| 0 | 43 | (55.84%) | 13 | 30 | 0.487 | |
| 1 | 14 | (18.18%) | 5 | 9 | ||
| 2 | 15 | (19.48%) | 2 | 13 | ||
| 3 | 5 | (6.49%) | 2 | 3 | ||
|
EGFR n = 69 |
total | 69 | 21 | 48 | ||
| negative | 56 | (81.16%) | 19 | 37 | 0.317 | |
| positive | 13 | (18.84%) | 2 | 11 | ||
|
ALK n = 73 |
total | 73 | 22 | 51 | ||
| negative | 59 | (80.82%) | 20 | 39 | 0.204 | |
| positive | 14 | (19.18%) | 2 | 12 | ||
a Chi-square test